

# Narita Memorial Proton Center, Japan, treats first patient with the treatment planning system RayStation

Narita Memorial Proton Center in Toyohashi, Japan, has treated its first patient using planning in RayStation. The system was used to plan a pencil beam scanning treatment (PBS) which was delivered to a prostate cancer patient by the IBA Proteus®ONE compact proton therapy solution. The center was established in April 2018, and this first patient treatment was conducted in early September.

The RayStation system at Narita Memorial Proton Center includes multi criteria optimization (MCO), which seeks to decrease manual planning time, provide a better understanding of tradeoffs between conflicting planning goals, and improve treatment plan quality.

Japan is one of the world's most technologically advanced treatment planning markets, and particle planning is continuously growing in the region. RaySearch has a strong user base in Japan and is a world-wide market leader for proton therapy planning software.

Takeshi Yanagi, Director Narita Memorial Proton Center, says: "It was smoother to create treatment plans than we expected. We really felt this was the right system for us when RaySearch could demonstrate that it will be possible to evaluate the treatment plans with respect to robustness."

Johan Löf, CEO of RaySearch, says: "We are very happy to see another state-of-the-art proton center in Japan using RayStation for its first clinical treatment. Narita Memorial Proton Center is recently established, and we are looking forward to many more years of successful cooperation."

#### **About Narita Memorial Proton Center**

The state-of-the-art proton facility Narita Memorial Proton Center was launched in April 2018 as a part of the Meiyokai Social Medical Corporation, founded in Toyohashi City in 1951. The Narita Memorial Proton center is the first proton center in the Tokai-region, and its mission includes "Aiming for advanced medical treatments based on kindness and warmth towards people".

#### About RayCare

RayCare\* represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

### **About RayStation**

RayStation integrates all RaySearch's advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch's market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

## About RaySearch

RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system and the RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. RaySearch's software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

More information about RaySearch is available at <u>www.raysearchlabs.com</u>

## For further information, please contact:

Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

Telephone: +46 (0)8-510 530 00 johan.lof@raysearchlabs.com

Peter Thysell, CFO, RaySearch Laboratories AB (publ)

Telephone: +46 (0)70 661 05 59 peter.thysell@raysearchlabs.com

<sup>\*</sup> Subject to regulatory clearance in some markets.